Last Updated on November 11, 2024 by The Health Master
JB Pharma’s formulations manufacturing facility – T20 located at Panoli, Gujarat was inspected by the US Food and Drugs Administration (USFDA). The inspection was conducted from June 5-9, 2023.
The company informed that at the end of the inspection, the facility received “No Observations” and thus no Form 483 was issued.
A statement from JB Pharma said, “The company remains committed to producing quality products, embedding a quality culture across the organisation and continuously investing in systems, processes and training of its employees so that it can maintain the highest standards of quality and compliance for all its markets.”
“We request you to take the above announcement on record.”
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
USFDA issues Form 483 with zero observation to Piramal
USFDA issues Form 483 with 10 observations to Lupin, Pithampur
USFDA issues Form 483 with 2 observations to Alembic, Gujarat
Action to be taken against Pharmacies offering abnormal discounts: Karnataka
USFDA gives approval for Cisatracurium Besylate injection
Drug recall: Typhoid vaccine recalled due to this reason
NPPA Guidelines: For change of Manufacturer in Notified Drug Formulations
Pharma Traders Association request time to withdraw recently banned 14 FDCs
IPC: These 5 countries recognize Indian Pharmacopoeia (IP)
394 Product Permissions of 14 banned FDCs to be cancelled: Gujarat
NPPA revised Ceiling price of 15 scheduled formulations: June 2023
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
